STOCK MARKET BSE NSE

Expert panel ponders upon restructuring of COVID vaccines against Omicron

NK Arora, head of COVID Working Group of the NTAGI, told that daily deliberations are on whether the existing vaccines in India can be specifically tailored against Omicron.

Published: 09th January 2022 09:05 AM  |   Last Updated: 09th January 2022 10:01 AM   |  A+A-

Covishield vaccine (L) and Covaxin (R)

Covishield vaccine (L) and Covaxin (R) (Photos | EPS)

Express News Service

NEW DELHI: An expert panel on COVID vaccines under the National Technical Advisory on Immunization is discussing the possibility of "restructuring and redesigning" of existing vaccines to make them more potent against the Omicron variant. 

The move assumes significance as current vaccines are largely ineffective against preventing infection from Omicron, even though there is some evidence that hospitalisations or deaths may be lower during the ongoing wave, due to vaccinations. 

NK Arora, head of COVID Working Group of the NTAGI, told that daily deliberations are on whether the existing vaccines in India can be specifically tailored against Omicron.

"Though our national COVID vaccination drive is getting expanded to provide precaution doses to the most vulnerable population groups, our interest at this point is also to push scientists and companies to redesign the vaccines so that they are better suited against Omicron and reduce transmission rates between vaccinated individuals," he said.

However, he did not specify which are the vaccines that can undergo the rapid restructuring required to target the variant that has triggered a massive wave in the country.

Sources in NTAGI said that Covaxin, for instance, which is made of the original whole inactivated SARS CoV 2 virus, can quickly be subjected to such an experiment.

"Like in some other countries, we too want to assess if the vaccines are changed intrinsically to be more efficient against preventing infection and disease due to Omicron," said the source. 

Many international vaccine makers such as Pfizer-BioNTech and Moderna have conceded that even three doses of may not be able to curb the rapid spread of the highly transmissible Omicron variant.

In India, there are no results available yet on the effect and efficacy of Covishield and Covaxin - the two vaccines largely used so far - in the context of Omicron.

Other brands also under consideration 

Sources said that there are considerations about how can other vaccines such as Corbebax, Novavax and ZyCoVD, can be better utilised to manage Omicron, which is spreading like wildfire



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp